India to Canada: Apixaban Export Trade Route

To import Apixaban formulations into Canada, the following approvals and registrations are mandatory:

1. Drug Identification Number (DIN): Each pharmaceutical product must obtain a DIN, an eight-digit number signifying Health Canada's approval of the product's safety, efficacy, and quality. The DIN application should include comprehensive product information, such as formulation details, manufacturing site specifics, and labeling.

2. Drug Establishment Licence (DEL): Importers must possess a valid DEL, authorizing them to import pharmaceutical products. The DEL application requires evidence of compliance with GMP standards and details of all foreign manufacturing sites involved in the production of the finished dosage forms.

3. Common Technical Document (CTD/eCTD) Format: Submissions to Health Canada should be in the CTD or electronic CTD (eCTD) format, facilitating a standardized review process.

4. Timelines and Fees: Approval timelines and associated fees can vary. Importers should consult Health Canada's current fee schedule and service standards for precise information.

5. GMP Inspection Requirements: Health Canada mandates that foreign manufacturing facilities comply with GMP standards. Importers must ensure that these facilities are listed on their DEL and may be subject to Health Canada's inspections to verify compliance.

Indian manufacturers exporting Apixaban formulations to Canada must adhere to the following GMP standards:

1. GMP Certification: Manufacturers must comply with GMP requirements as outlined in Part C, Division 2 of the Food and Drug Regulations. This includes maintaining high-quality manufacturing processes and ensuring product safety and efficacy.

2. Health Canada Approval: Manufacturing facilities must be listed on the importer's DEL, indicating Health Canada's recognition of their compliance with GMP standards.

3. Recent Inspections and Regulatory Actions: Health Canada regularly inspects foreign manufacturing sites to ensure ongoing compliance. Importers should monitor Health Canada's Drug and Health Product Inspections database for updates on inspections and any regulatory actions taken against Indian pharmaceutical companies.

Several regulatory changes between 2024 and 2026 have impacted Indian pharmaceutical exports to Canada:

1. Revised GMP Regulations in India: In January 2024, India's Ministry of Health published revised GMP regulations to align with global standards, particularly those of the World Health Organization. These revisions aim to enhance the quality of pharmaceutical products and may affect the approval process for Indian manufacturers exporting to Canada.

2. Health Canada's Updated Import Policies: In late 2024, Health Canada updated its guidance on importing health products for commercial use, emphasizing the need for importers to provide comprehensive documentation, including valid DELs and evidence of GMP compliance for foreign manufacturing sites.

3. Mutual Recognition Agreements (MRAs): As of March 2026, Canada has been actively engaging in MRAs with various countries to recognize equivalent GMP inspection processes. While specific agreements with India are not currently in place, ongoing discussions may influence future import requirements.

Importers and exporters should stay informed about these developments to ensure compliance with evolving regulatory requirements.

In 2025, the Canadian anticoagulants market was valued at approximately USD 2,507.2 million, with projections indicating growth to USD 3,860.7 million by 2033, reflecting a compound annual growth rate (CAGR) of 5.7% from 2026 to 2033. Apixaban, marketed under the brand name Eliquis, is a leading direct oral anticoagulant (DOAC) in Canada, widely prescribed for conditions such as atrial fibrillation and venous thromboembolism. The increasing prevalence of these conditions, coupled with an aging population and comprehensive healthcare coverage, drives the demand for Apixaban formulations. While Canada has domestic pharmaceutical manufacturing capabilities, a significant portion of Apixaban formulations is imported to meet the growing demand.

Canada maintains a Most-Favored-Nation (MFN) import duty rate of 0% for pharmaceutical products classified under HS code 30049099, which includes finished formulations containing Apixaban. Additionally, pharmaceutical imports are generally exempt from the Goods and Services Tax (GST). There are no specific Free Trade Agreements (FTAs) between Canada and India that alter this duty structure for pharmaceutical products. Currently, there are no anti-dumping duties imposed on Apixaban formulations imported into Canada.

India is a major supplier of Apixaban formulations to Canada, accounting for 18.3% of India's total Apixaban formulation exports, valued at $33.0 million USD across 673 shipments from 13 Indian manufacturers/exporters. The top Indian exporters include APOTEX RESEARCH PRIVATE LIMITED ($17.8M), INTAS PHARMACEUTICALS LIMITED ($2.6M), and UNISON PHARMACEUTICALS PRIVATE LIMITED ($2.1M). The primary Canadian buyers are APOTEX INC ($7.0M) and JAMP PHARMA CORPORATION ($1.3M). Other major countries supplying Apixaban to Canada include Ireland and Paraguay. India's competitive pricing and established manufacturing capabilities position it favorably against competitors from the European Union and other regions.

India is a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic medicines by volume as of 2024. The country's pharmaceutical industry is valued at over USD 50 billion, with exports accounting for more than USD 25 billion. India's manufacturing capabilities are supported by over 650 U.S. FDA-approved facilities, surpassing the United States in the number of FDA-registered generic manufacturing sites. This extensive infrastructure enables the production of a wide range of finished dosage forms, including tablets, capsules, syrups, and injections. The cost-effectiveness of Indian pharmaceutical manufacturing is attributed to economies of scale, a skilled workforce, and favorable regulatory policies. Additionally, India houses 2,050 WHO-GMP-certified and 286 EDQM-approved plants as of 2024, ensuring compliance with international quality standards.

India's Apixaban formulations are competitively priced compared to those from China and the European Union. The cost advantages stem from India's efficient manufacturing processes and lower labor costs. Quality perception is high, with Indian manufacturers adhering to stringent regulatory standards, including approvals from the U.S. FDA and WHO-GMP certifications. In Canada, Indian pharmaceutical products are well-accepted, with a significant share of generic drugs imported from India. Supply reliability is bolstered by India's robust manufacturing infrastructure and a track record of consistent delivery to international markets. While specific pricing data for Apixaban formulations is proprietary, Indian generics are generally more affordable than their European counterparts, without compromising on quality.

The India-Canada supply chain for Apixaban formulations is characterized by high reliability. Indian manufacturers possess substantial capacity for producing finished dosage forms, supported by advanced packaging and cold chain logistics. As of 2024, India has over 650 U.S. FDA-approved manufacturing facilities, ensuring compliance with international regulatory standards. There have been no significant supply disruptions reported in recent years. Leading Indian pharmaceutical companies have announced expansion plans to further increase production capacities, ensuring the ability to meet growing international demand.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Apixaban formulations.

• Understand Minimum Order Quantities (MOQs): Indian suppliers typically have MOQs that vary based on the formulation and packaging requirements. Establish clear communication to align on order sizes that meet both parties' needs.

• Negotiate Favorable Payment Terms: Common payment terms in India-Canada pharmaceutical trade include letters of credit and advance payments. Negotiate terms that balance cash flow considerations with supplier trust.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on their regulatory compliance history, manufacturing capabilities, quality control measures, and past performance in international markets.

• Stay Informed on Regulatory Changes: Regularly monitor updates from Health Canada and the Central Drugs Standard Control Organisation (CDSCO) to ensure ongoing compliance with import regulations and quality standards.

By meticulously following these guidelines, Canadian companies can ensure the selection of reliable Indian suppliers for Apixaban formulations, maintaining compliance with Health Canada's regulations and safeguarding product quality.